Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.

Author: ChildressAnn C, CutlerAndrew J, Ferreira-CornwellM Celeste, FindlingRobert L, GasiorMaria, HamdaniMohamed, SquiresLiza

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Lisdexamfetamine dimesylate (LDX) was effective in treating adolescent ADHD and demonstrated a safety profile consistent with previous LDX studies.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To examine lisdexamfetamine dimesylate (LDX) efficacy and safety versus placebo in adolescents with attention-deficit/hyperactivity disorder (ADHD). METHOD: Adolescents (13 through 17) with at least moderately symptomatic ADHD (ADHD Rating Scale IV: Clinician Version [ADHD-RS-IV] score ≥...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jaac.2011.01.007

データ提供：米国国立医学図書館（NLM）

Lisdexamfetamine Dimesylate: A New Hope for Adolescents with ADHD?

In the bustling desert of adolescence, attention-deficit/hyperactivity disorder (ADHD) can make it difficult to navigate the challenges of school, social interactions, and personal growth. This study explores the efficacy and safety of lisdexamfetamine dimesylate (LDX), a medication specifically designed to address ADHD symptoms. The researchers conducted a 4-week, double-blind study comparing LDX to placebo in adolescents with ADHD. The study found that LDX significantly improved ADHD symptoms, demonstrating its potential as a viable treatment option.

LDX: A Promising Treatment for Adolescent ADHD

The study's findings suggest that LDX is an effective treatment for ADHD in adolescents, leading to significant improvements in symptoms and overall functioning.

Finding the Right Path for Managing ADHD

This study offers hope for adolescents struggling with ADHD, suggesting that LDX may be a helpful tool for managing their condition. However, it's essential to consult with a healthcare professional to determine the most appropriate treatment approach for each individual.

Dr.Camel's Conclusion

This study demonstrates the effectiveness of LDX in treating adolescent ADHD, offering a promising new treatment option for managing symptoms and improving quality of life. It's crucial to discuss treatment options with a healthcare professional to determine the best course of action for each individual.

Date :
  1. Date Completed 2012-09-21
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

21421179

DOI: Digital Object Identifier

10.1016/j.jaac.2011.01.007

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.